Although these studies focused on the impact of PBRM1 mutations, ccRCC patients also harbor other secondary mutations, such as BAP1 and SETD2, which might affect ICB response in different ways. This evidence concerns the gene BAP1 and nonpapillary renal cell carcinoma.